A decision analysis led to the surprising conclusion that health outcomes would be maximized and costs minimized by eliminating lung imaging altogether.
Investigators constructed a decision model to determine the most cost-effective diagnostic strategy for pulmonary embolism (PE). They evaluated 60 strategies that differed according to tests used, test order, and values of numerous parameters (e.g., cutoff for a “normal” d-dimer result). The diagnostic tests were d-dimer measurement, lower-extremity compression ultrasonography, computed tomography (CT) pulmonary angiography, and ventilation-perfusion scanning. The analysis relied on numerous assumptions, most importantly that 1.96% of patients tested for PE actually had PE.
The most cost-effective strategy was as follows: (1) Categorize risk using Wells score modified by whether deep venous thrombosis is clinically evident; (2) measure d-dim…
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals